NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Eli Lilly stock delivered ~40% since my initial bullish article. Novo pressures with oral Semaglutide and CagriSema, but that is just a timing issue before Retatrutide + Orforglipron take the stage.

Eli Lilly and Company remains a Buy, supported by robust incretin-driven growth and strategic expansion in obesity treatments. LLY pivots from scarcity to access economics, prioritizing volume over ...

Eli Lilly LLY-0.35%decrease; red down pointing triangle and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity ...

Novo Nordisk was the first company to introduce GLP-1 weight loss drugs. Eli Lilly's GLP-1 drugs have since taken the lead in the emerging weight loss space. But Novo Nordisk now has a new pill ...

Eli Lilly LLY-0.87%decrease; red down pointing triangle is in advanced talks to acquire Ventyx Biosciences VTYX 0.04%increase; green up pointing triangle for around $1 billion, according to people ...

Attorney General Todd Rokita is suing one of Indiana's largest companies, Eli Lilly and Co., alleging the company conspired with other drug manufacturers to artificially inflate the price of insulin ...